Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma, HCN-NOS, or HCC
NCT04634357Phase 2Recruiting
- Sponsor
- Eureka Therapeutics, Inc.
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ET140203 in hepatoblastoma, hepatocellular carcinoma (HCC) and hepatocellular neoplasm, sponsored by Eureka Therapeutics, Inc. Primary endpoints: Incidence rates of adverse events at 28 days, Severity rates of adverse events at 28 days and 2 more. Started Jul 2022; status: recruiting.
02
Drugs
ET140203
03
Conditions
hepatoblastomahepatocellular carcinoma (HCC)hepatocellular neoplasm
Beyond the preview
Go deeper on NCT04634357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634357.